Skip to main content

Medicare Reconsiders Coverage for PET Beta Amyloid Imaging in Alzheimer's Disease: A Shift Towards Personalized Care

 Introduction:

As long time readers know, Medicare periodically reviews its national coverage policies for medical services. This includes the consideration of National Coverage Determinations (NCDs) regarding whether specific items or services should be covered nationally. One such NCD pertains to PET beta amyloid imaging for dementia and neurodegenerative disease.



Background:

In 2013, Medicare established the NCD for PET beta amyloid scans as a part of Coverage with Evidence Development (CED) studies. The current NCD allows for coverage of a single PET beta amyloid scan when provided through a clinical trial that has been reviewed and approved by CMS. All other use cases are non-covered.

There has been considerable stakeholder criticism that the NCD was overly restrictive and impacted Medicare beneficiary's ability to access care. However, with advances in medical care, standards of practice, and the development of promising anti-amyloid treatments, the application of amyloid PET scans has evolved.

Shift in Focus:

In response to stakeholder feedback and the availability of new evidence, Medicare is now considering two key questions:

  1. Should the requirement for CED in PET beta amyloid imaging be removed?
  2. Should Medicare remove the current NCD for beta amyloid PET in dementia and neurodegenerative disease?

Advancements in Alzheimer's Care:

The landscape of Alzheimer's disease (AD) care has significantly changed since Medicare finalized its CED coverage for PET Beta Amyloid Imaging in 2013. Treatment approaches now emphasize addressing health risk factors and comorbidities. With the rise in development of anti-amyloid drug treatments showing promise in modifying AD pathophysiology, many have questioned whether the current national policy restricting PET scans would serve as a barrier to these treatments.

Importance of Brain Amyloid Confirmation:

With the introduction of new pharmacological treatments such as Leqembi, confirming the presence of brain amyloid through PET scans has become crucial for appropriate patient selection. This ensures that patients receive treatments tailored to their individual characteristics, reducing the risk of unnecessary treatment harms.

The Role of Local Coverage Determinations:

With its proposed policy, CMS would rescind the national coverage policy and empower local Medicare Administrative Contractors (MACs) with the discretion to make coverage determinations regarding PET beta amyloid imaging. This flexibility allows prompt responses to new evidence on proven treatments for individual patients.

While the Local Coverage Determination process is, in fact, more nimble than the national process it still requires the MACs to review clinical evidence and allow for public notice and comment before they establish any new policy.

Addressing Health Disparities:

AD prevalence varies across racial and ethnic groups, with Blacks and Hispanics having a higher likelihood of AD compared to Whites. However, they are less likely to have a diagnosis due to various factors, including differing beliefs about AD and higher rates of discrimination in dementia healthcare.

Conclusion:

In light of advancements in medical care and the development of new anti-amyloid treatments, Medicare is proposing to remove the NCD for PET beta amyloid imaging. This decision aims to provide more personalized care for AD patients and reduce the burden on providers and patients. By empowering MACs to make coverage determinations, Medicare seeks to adapt to the evolving landscape of Alzheimer's care and address health disparities in dementia research and treatment.

The proposal to remove the NCD and end the provisional CED coverage for PET beta amyloid imaging is open for public comments until August 16, 2023.

Comments

Post a Comment

Popular posts from this blog

The Problem of Limited-Supply Agreements for Medicare Price Negotiation

A recent JAMA Viewpoint article discusses how limited-supply agreements between brand name and generic drug makers could impact Medicare price negotiation under the Inflation Reduction Act (IRA). These agreements allow brand manufacturers to maintain some market exclusivity by limiting the supply of generic competitors. The article suggests these deals may increase as the Centers for Medicare and Medicaid Services (CMS) implements the IRA's price negotiation provisions. From a business perspective, it's understandable why brand manufacturers might find limited-supply agreements preferable to having their drugs subject to Medicare negotiation. Maintaining even partial exclusivity is likely better for revenue than triggering government-dictated price reductions. However, policymakers and patients are increasingly concerned that these deals keep prices high despite generic availability. The use of limited supply agreements could also produce unintended consequences.  Balancing som...
Post a Comment
Read more

FDA Green Light Inches Genetic Screening Forward

The FDA recently granted authorization for the first multi-gene test for assessing hereditary cancer risk, marking a significant advancement in genetic screening capabilities. Developed by Invitae Corporation, the Invitae Common Hereditary Cancers Panel analyzes variants in 47 genes associated with increased cancer risk. Using next-generation sequencing on DNA from blood samples, the test looks at BRCA1 and BRCA2 variants linked to breast and ovarian cancer, as well as other cancer-related genes.  (image source: Adobe Stock Images) The FDA’s approval provides a regulatory framework giving labs a clearer roadmap for developing similar multi-gene panels. With an authorized model in place, labs can proceed more confidently in navigating FDA submissions. Specifically, the de novo classification created for Invitae’s test allows future lab-developed panels to gain regulatory clearance through the expedited 510(k) pathway by demonstrating substantial equivalence. This streamlined validat...
Post a Comment
Read more

The Future of Liquid Biopsies: Endless Possibilities for Cancer Testing

Liquid biopsies are poised to disrupt cancer testing as we know it. These novel blood tests analyze circulating tumor DNA (ctDNA) and other molecules released by cancer cells, providing a non-invasive option for detection, diagnosis, and monitoring. The promise of liquid biopsies has generated tremendous excitement, along with over $1 billion in investments and acquisitions in recent years. But how close are we to realizing their full potential?  A recent review article sounds a note of caution amidst the hype. While liquid biopsies show ability to detect cancer, evidence that they improve patient outcomes is still lacking. Randomized trials with survival endpoints are needed to prove clinical utility. However, this provides the perfect opportunity for innovative diagnostics companies. Rather than dampening enthusiasm, these evidence gaps highlight major growth possibilities if companies can demonstrate real-world value.   We envision liquid biopsies transforming oncology...
Post a Comment
Read more